Vi-DT伤寒结合疫苗与含麻疹风疹腮腺炎疫苗在9-15月龄尼泊尔婴儿中的免疫非干扰性和安全性研究
在尼泊尔9-15月龄健康婴儿中开展的随机、开放标签III期研究,360名参与者随机均分为Vi-DT+MMR组和MMR单独组,评估免疫原性和安全性。结果显示MMR疫苗与Vi-DT无免疫干扰,两组不良事件相当,Vi-DT结合疫苗可考虑加入EPI程序。
要点
- Vi-DT+MMR组与MMR单独组的抗麻疹、抗腮腺炎、抗风疹血清阳性率差异的95%CI下限均未低于-10%。
- 仅抗腮腺炎血清阳性率差异的95%CI下限未满足非劣效标准,但可能无临床意义。
- 两组在征集性和非征集性不良事件方面相当,未报告安全性问题。
核心结论
- 结果表明MMR疫苗与Vi-DT无免疫干扰,Vi-DT结合疫苗可考虑作为EPI程序的补充用于有伤寒风险的儿童。
研究设计与样本
- 随机、开放标签、III期研究,在尼泊尔9-15月龄健康婴儿中评估Vi-DT伤寒结合疫苗与MMR疫苗同时接种的免疫非干扰性、安全性和反应原性。
- 共纳入360名参与者,随机均分为Vi-DT+MMR组(180人)和MMR单独组(180人),接种后28天评估免疫原性和安全性。
主要发现
- Vi-DT+MMR组 vs MMR单独组的抗麻疹血清阳性率差异为-2.73%(95%CI -8.85, 3.38)。
- Vi-DT+MMR组 vs MMR单独组的抗腮腺炎血清阳性率差异为-3.19%(95%CI -11.25, 4.88),仅该差异的95%CI下限未满足-10%的非劣效标准,可能无临床意义。
- Vi-DT+MMR组 vs MMR单独组的抗风疹血清阳性率差异为2.91%(95%CI -3.36, 9.18)。
- 上述结果在符合方案集中得到确认。
- 两组在征集性和非征集性不良事件方面相当,未报告安全性问题。
临床怎么用
- 作者认为MMR疫苗与Vi-DT无免疫干扰,Vi-DT结合疫苗可考虑作为EPI程序的补充用于有伤寒风险的儿童。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Typhoid fever is a common disease in developing countries especially in the Indian subcontinent and Africa. The available typhoid conjugate vaccines (TCV) have been found to be highly immunogenic in infants and children less than 2 years of age. Many countries are planning to adopt TCV in their routine EPI programs around 9 months of age when measles containing vaccines are given. Therefore, Vi-DT TCV was tested in 9-15 months aged healthy infants in Nepal to demonstrate non-interference with a measles containing vaccine. METHODS: This was a randomized, open label, phase III study to assess the immune non-interference, safety, and reactogenicity of Vi-DT typhoid conjugate vaccine when given concomitantly with measles, mumps and rubella (MMR) vaccine. A total of 360 participants aged 9-15 months were enrolled and randomized equally into Vi-DT + MMR (180 participants) or MMR alone (180 participants) group and were evaluated for immunogenicity and safety 28 days post vaccination. RESULTS: Using the immunogenicity set, difference between proportions (95% CI) of the Vi-DT + MMR group vs MMR alone group were -2.73% (-8.85, 3.38), -3.19% (-11.25, 4.88) and 2.91% (-3.36, 9.18) for sero-positivity rate of anti-measles, anti-mumps and anti- rubella, respectively. Only the lower bound of the range in difference of the proportions for sero-positivity rate of anti-mumps did not satisfy the non-inferiority criteria as it was above the -10% limit, which may not be of clinical significance. These results were confirmed in the per protocol set. There were no safety concerns reported from the study and both Vi-DT + MMR and MMR alone groups were comparable in terms of solicited and unsolicited adverse events . CONCLUSIONS: Results indicated that there is non-interference of MMR vaccine with Vi-DT and Vi-DT conjugate vaccine could be considered as an addition to the EPI schedule among children at risk of contracting typhoid.
引用
- Saluja T, Rai GK, Chaudhary S, et al. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants. Vaccine. 2022. PMID: 36064672. doi:10.1016/j.vaccine.2022.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。